<DOC>
	<DOCNO>NCT01728077</DOCNO>
	<brief_summary>N01372 study evaluate long-term safety , tolerability , maintenance efficacy Brivaracetam ( BRV ) ; well effect BRV subject ' health-related quality life explore direct medical resource use BRV ( subject enter N01372 study pharmacoeconomic data collect ) . BRV use dos maximum 200 mg/day , adjunctive treatment subject age 16 year old Epilepsy .</brief_summary>
	<brief_title>Evaluation Long-term Safety , Efficacy Brivaracetam ( BRV ) Used Adjunctive Treatment Subjects With Epilepsy</brief_title>
	<detailed_description>Flexible dose 200 mg/day , twice daily ( 10 , 25 50 mg oral film-coated tablet ) . The study continue either regulatory approval BRV grant Health Authority indication adjunctive treatment Epilepsy , Sponsor decide close study , BRV development stop Sponsor .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subject male female 16 year old . Subjects 18 year age may include legally permit ethically accepted Subjects complete Treatment Period applicable previous BRV study , access present study Subject investigator believe reasonable benefit longterm administration BRV may expect Female subject without childbearing potential ( postmenopausal least 2 year , bilateral oophorectomy tubal ligation , complete hysterectomy ) eligible . Female subject childbearing potential eligible use medically accept contraceptive method Subjects must able take oral filmcoated tablet BRV Subject develop hypersensitivity component Investigational Medicinal Product ( IMP ) comparative drug state protocol course prior study Severe medical , neurological , psychiatric disorder , laboratory value may impact safety subject Poor compliance visit schedule medication intake previous BRV study Planned participation clinical study another investigational drug device study Pregnant lactate woman Any medical condition , investigator 's opinion , warrant exclusion Subject lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either question 4 question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) last visit previous study Entry Visit study complete last visit previous study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Brivaracetam</keyword>
	<keyword>Long-term Follow-up</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Adjunctive treatment</keyword>
</DOC>